Table 1.
Clinical characteristics of patients at the time of enrollment.
| AOSD (n = 60) | RA (n = 16) |
HC (n = 34) |
||
|---|---|---|---|---|
|
Active (n = 39) |
Inactive (n = 21) |
|||
| Age (year) | 36.0 ± 12.5 | 36.0 ± 13.8 | 55.5 ± 12.4 | 39.0 ± 10.8 |
| Gender (F/M) | 29/10 | 15/6 | 13/3 | 24/10 |
| Duration (months) | 15.0 ± 22.2 | 17.0 ± 23.4 | 18.1 ± 16.4 | |
| Clinical features | ||||
| Fever | 35 (89.7) | 0 (0.0) | ||
| Sore throat | 27 (69.2) | 0 (0.0) | ||
| Skin rash | 31 (79.5) | 0 (0.0) | ||
| Lymphadenopathy | 28 (71.8) | 3 (14.3) | ||
| Splenomegaly | 15 (38.5) | 0 (0.0) | ||
| Hepatomegaly | 1 (2.6) | 0 (0.0) | ||
| Pericarditis | 8 (20.5) | 0 (0.0) | ||
| Pleuritis | 10 (25.6) | 0 (0.0) | ||
| Pneumonia | 18 (46.2) | 0 (0.0) | ||
| Myalgia | 14 (35.9) | 0 (0.0) | ||
| Arthralgia | 35 (89.7) | 0 (0.0) | 16 (100.0) | |
| Arthritis | 7 (17.9) | 0 (0.0) | 16 (100.0) | |
| Systemic score | 5.9 ± 1.9 | 0.2 ± 0.4 | ||
| Laboratory markers | ||||
| Hemoglobin, g/L | 110.7 ± 26.3 | 131.8 ± 17.2 | 122.9 ± 12.8 | |
| Leukocyte, × 109/L | 16.7 ± 5.7 | 8.0 ± 2.7 | 6.8 ± 2.2 | |
| Platelet, × 109/L | 279.2 ± 115.0 | 232.4 ± 76.4 | 221.9 ± 68.0 | |
| ESR, mm/h | 68.6 ± 26.8 | 19.6 ± 29.6 | 47.2 ± 28.8 | |
| CRP, mg/L | 93.1 ± 60.0 | 23.6 ± 24.5 | 14.7 ± 36.1 | |
| ALT, U/L | 61.5 ± 60.4 | 23.0 ± 11.6 | 14.7 ± 5.9 | |
| AST, U/L | 46.9 ± 25.6 | 18.6 ± 7.4 | 21.0 ± 2.6 | |
| Ferritin, ng/ml | 2779.0 ± 4286.0 | 210.2 ± 207.4 | ||
| ANA positivity | 6 (14.6) | 1 (4.8) | 5 (31.2) | |
| RF positivity | 2 (4.9) | 0 (0.0) | 14 (87.5) | |
| ACPA positivity | 0 (0.0) | 1 (4.8) | 9 (56.3) | |
| Treatments | ||||
| Steroids and sDMARDs naïve | 18 (46.2) | 8 (38.1) | 3 (18.8) | |
| Low dosage of steroid monotherapy | 2 (5.1) | 1 (4.8) | 0 (0.0) | |
| High dosage of steroid monotherapy | 4 (10.3) | 0 (0.0) | 0 (0.0) | |
| sDMARD(s) | 0 (0.0) | 3 (14.2) | 8 (50.0) | |
| Combination therapy, steroids + sDMARD(s) | 15 (38.4) | 9 (42.9) | 5 (31.2) | |
All values are presented as n (percent) or mean ± SD.
AOSD, adult onset Still's disease; HC, healthy control; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; AST, aspartate transaminase; ALT, alanine transaminase; ANA, anti-nuclear antibody; RF, rheumatoid factor; ACPA, anticitrullinated peptide antibodies; sDMARD, synthetic disease-modifying antirheumatic drug.